Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mother-to-infant fecal microbiota transplantation
- Development stage
- Unknown
- Lead developer
- Copenhagen Prospective Studies on Asthma in Childhood
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Mother-to-infant fecal microbiota transplantation (FMT) and fecal virome transplantation (FVT) are investigational microbiome-based therapies being evaluated in the **RestoreGut** trial. Led by **Professor Klaus Bønnelykke** at the Copenhagen Prospective Studies on Asthma in Childhood (COPSAC), the treatment aims to correct gut dysbiosis in infants born via cesarean section. C-section infants often lack the maternal vaginal and fecal microbes typically acquired during vaginal birth, which is linked to an increased risk of immune-mediated diseases such as asthma and allergies. The procedure involves transferring processed maternal fecal matter—containing a diverse community of bacteria (FMT) or specifically isolated viruses and phages (FVT)—to the infant shortly after birth to seed a healthy, "vaginal-like" microbiome and promote proper immune system maturation.
- Other names
- Maternal FMTMaternal FVTMother-to-infant fecal virome transplantationMaternal fecal microbiota transplantation
Beyond the preview
Go deeper on mother-to-infant fecal microbiota transplantation.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mother-to-infant fecal microbiota transplantation.